1     
OPIOID ABUSE PREVENTION AND TREATMENT

2     
AMENDMENTS

3     
2017 GENERAL SESSION

4     
STATE OF UTAH

5     
Chief Sponsor: Steve Eliason

6     
Senate Sponsor: Brian E. Shiozawa

7     Cosponsors:
8     Rebecca Chavez-Houck
9     Brad M. Daw
Craig Hall
Sandra Hollins
Michael S. Kennedy
Michael E. Noel
10     

11     LONG TITLE
12     General Description:
13          This bill requires controlled substance prescribers to receive training in a nationally
14     recognized opioid abuse screening method and requires reimbursement for the
15     screening services.
16     Highlighted Provisions:
17          This bill:
18          ▸     requires controlled substance prescribers to receive training in a nationally
19     recognized opioid abuse screening method;
20          ▸     permits controlled substance prescribers to fulfill continuing education requirements
21     through training in the screening method;
22          ▸     permits controlled substance prescribers who receive a DATA 2000 waiver to use
23     the waiver to fulfill certain continuing education requirements;
24          ▸     requires Medicaid reimbursement to health care providers for screening services;
25          ▸     requires the Public Employees' Benefit and Insurance Program to reimburse health
26     care providers for screening services; and
27          ▸     makes technical changes.
28     Money Appropriated in this Bill:

29          None
30     Other Special Clauses:
31          None
32     Utah Code Sections Affected:
33     AMENDS:
34          58-37-6.5, as repealed and reenacted by Laws of Utah 2013, Chapter 450
35     ENACTS:
36          26-18-21, Utah Code Annotated 1953
37          49-20-414, Utah Code Annotated 1953
38     

39     Be it enacted by the Legislature of the state of Utah:
40          Section 1. Section 26-18-21 is enacted to read:
41          26-18-21. Screening, Brief Intervention, and Referral to Treatment Medicaid
42     reimbursement.
43          (1) As used in this section:
44          (a) "Controlled substance prescriber" means a controlled substance prescriber, as that
45     term is defined in Section 58-37-6.5, who:
46          (i) has a record of having completed SBIRT training, in accordance with Subsection
47     58-37-6.5(2), before providing the SBIRT services; and
48          (ii) is a Medicaid enrolled health care provider.
49          (b) "SBIRT" means the same as that term is defined in Section 58-37-6.5.
50          (2) The department shall reimburse a controlled substance prescriber who provides
51     SBIRT services to a Medicaid enrollee who is 13 years of age or older for the SBIRT services.
52          Section 2. Section 49-20-414 is enacted to read:
53          49-20-414. Screening, Brief Intervention, and Referral to Treatment program
54     reimbursement.
55          (1) As used in this section:
56          (a) "Controlled substance prescriber" means a controlled substance prescriber, as that

57     term is defined in Section 58-37-6.5, who:
58          (i) has a record of having completed SBIRT training, in accordance with Subsection
59     58-37-6.5(2), before providing the SBIRT services; and
60          (ii) is a program enrolled controlled substance prescriber.
61          (b) "SBIRT" means the same as that term is defined in Section 58-37-6.5.
62          (2) The health program offered to the state employee risk pool under Section
63     49-20-202 shall reimburse a controlled substance prescriber who provides SBIRT services to a
64     covered individual who is 13 years of age or older for the SBIRT services.
65          Section 3. Section 58-37-6.5 is amended to read:
66          58-37-6.5. Continuing education for controlled substance prescribers.
67          (1) For the purposes of this section:
68          (a) "Controlled substance prescriber" means an individual, other than a veterinarian,
69     who:
70          (i) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah
71     Controlled Substances Act; and
72          (ii) possesses the authority, in accordance with the individual's scope of practice, to
73     prescribe schedule II controlled substances and schedule III controlled substances that are
74     applicable to opioid narcotics, hypnotic depressants, or psychostimulants.
75          (b) "D.O." means an osteopathic physician and surgeon licensed under Title 58,
76     Chapter 68, Utah Osteopathic Medical Practice Act.
77          [(b)] (c) "FDA" means the United States Food and Drug Administration.
78          [(c)] (d) "M.D." means a physician and surgeon licensed under Title 58, Chapter 67,
79     Utah Medical Practice Act.
80          [(d) "D.O." means an osteopathic physician and surgeon licensed under Title 58,
81     Chapter 68, Utah Osteopathic Medical Practice Act.]
82          (e) "SBIRT" means the Screening, Brief Intervention, and Referral to Treatment
83     approach used by the federal Substance Abuse and Mental Health Services Administration or
84     defined by the division, in consultation with the Division of Substance Abuse and Mental

85     Health, by administrative rule, in accordance with Title 63G, Chapter 3, Utah Administrative
86     Rulemaking Act.
87          (2) (a) Beginning with the licensing period that begins after January 1, 2014, as a
88     condition precedent for license renewal, each controlled substance prescriber shall complete at
89     least four continuing education hours per licensing period that satisfy the requirements of
90     Subsections (3) and (4).
91          (b) (i) Beginning with the licensing period that begins after January 1, 2024, as a
92     condition precedent for license renewal, each controlled substance prescriber shall complete at
93     least 3.5 continuing education hours in an SBIRT-training class that satisfies the requirements
94     of Subsection (5).
95          (ii) Completion of the SBIRT-training class, in compliance with Subsection (2)(b)(i),
96     fulfills the continuing education hours requirement in Subsection (4) for the licensing period in
97     which the class was completed.
98          (iii) A controlled substance prescriber:
99          (A) need only take the SBIRT-training class once during the controlled substance
100     prescriber's licensure in the state; and
101          (B) shall provide a completion record of the SBIRT-training class in order to be
102     reimbursed for SBIRT services to patients, in accordance with Section 26-18-21 and Section
103     49-20-414.
104          (3) As provided in Subsection 58-37f-402(8), the online tutorial and passing the online
105     test described in Section 58-37f-402 shall count as 1/2 hour of continuing professional
106     education under Subsection (2) per licensing period.
107          (4) A controlled substance prescriber shall complete at least 3.5 hours of continuing
108     education [hours] in one or more controlled substance prescribing classes, except dentists who
109     shall complete at least [2 such] two hours, that satisfy the requirements of Subsections (5) and
110     (7).
111          (5) A controlled substance prescribing class shall:
112          (a) satisfy the division's requirements for the continuing education required for the

113     renewal of the controlled substance prescriber's respective license type;
114          (b) be delivered by an accredited or approved continuing education provider
115     recognized by the division as offering continuing education appropriate for the controlled
116     substance prescriber's respective license type; and
117          (c) include a postcourse knowledge assessment.
118          (6) An M.D. or D.O. completing continuing professional education hours under
119     Subsection (4) shall complete those hours in classes that qualify for the American Medical
120     Association Physician's Recognition Award Category 1 Credit.
121          (7) The 3.5 hours of the controlled substance prescribing classes under Subsection (4)
122     shall include educational content covering the following:
123          (a) the scope of the controlled substance abuse problem in Utah and the nation;
124          (b) all elements of the FDA Blueprint for Prescriber Education under the FDA's
125     Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation
126     Strategy, as published July 9, 2012, or as it may be subsequently revised;
127          (c) the national and Utah-specific resources available to prescribers to assist in
128     appropriate controlled substance and opioid prescribing;
129          (d) patient record documentation for controlled substance and opioid prescribing; and
130          (e) office policies, procedures, and implementation.
131          (8) (a) The division, in consultation with the Utah Medical Association Foundation,
132     shall determine whether a particular controlled substance prescribing class satisfies the
133     educational content requirements of Subsections (5) and (7) for an M.D. or D.O.
134          (b) The division, in consultation with the applicable professional licensing boards,
135     shall determine whether a particular controlled substance prescribing class satisfies the
136     educational content requirements of Subsections (5) and (7) for a controlled substance
137     prescriber other than an M.D. or D.O.
138          (c) The division may by rule establish a committee that may audit compliance with the
139     Utah Risk Evaluation and Mitigation Strategy (REMS) Educational Programming Project
140     grant, that satisfies the educational content requirements of Subsections (5) and (7) for a

141     controlled substance prescriber.
142          (9) A controlled substance prescribing class required under this section:
143          (a) may be held:
144          (i) in conjunction with other continuing professional education programs; and
145          (ii) online; and
146          (b) does not increase the total number of state-required continuing professional
147     education hours required for prescriber licensing.
148          (10) The division may establish rules, in accordance with Title 63G, Chapter 3, Utah
149     Administrative Rulemaking Act, to implement this section.
150          (11) A controlled substance prescriber who, on or after July 1, 2017, obtains a waiver
151     to treat opioid dependency with narcotic medications, in accordance with the Drug Addiction
152     Treatment Act of 2000, 21 U.S.C. Sec. 823 et seq., may use the waiver to satisfy the 3.5 hours
153     of the continuing education requirement under Subsection (4) for two consecutive licensing
154     periods.